Xenetic Biosciences Valuation
| XBIO Stock | USD 4.31 0.15 3.61% |
At this time, the company appears to be overvalued. Xenetic Biosciences maintains a prevalent Real Value of $3.62 per share. The last-minute price of the company is $4.31. Our model calculates the value of Xenetic Biosciences from examining the company fundamentals such as Profit Margin of (1.86) %, current valuation of (191.14 K), and Return On Asset of -0.29 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Xenetic Biosciences' valuation include:
Price Book 0.9448 | Enterprise Value | Enterprise Value Ebitda 1.0257 | Price Sales 2.6372 | Enterprise Value Revenue 0.0159 |
Overvalued
Today
Please note that Xenetic Biosciences' price fluctuation is relatively risky at this time. Calculation of the real value of Xenetic Biosciences is based on 3 months time horizon. Increasing Xenetic Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Xenetic Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Xenetic Stock. However, Xenetic Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.31 | Real 3.62 | Target 40.0 | Hype 4.31 | Naive 4.11 |
The intrinsic value of Xenetic Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Xenetic Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Xenetic Biosciences helps investors to forecast how Xenetic stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Xenetic Biosciences more accurately as focusing exclusively on Xenetic Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Xenetic Biosciences' intrinsic value based on its ongoing forecasts of Xenetic Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Xenetic Biosciences' closest peers.
Xenetic Biosciences Cash |
|
Xenetic Valuation Trend
Knowing Xenetic Biosciences' actual value is paramount for traders when making sound investment determinations. Using both Xenetic Biosciences' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Xenetic Biosciences Total Value Analysis
Xenetic Biosciences is at this time forecasted to have valuation of (191.14 K) with market capitalization of 6.65 M, debt of 809.59 K, and cash on hands of 14.93 M. The negative valuation of Xenetic Biosciences may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Xenetic Biosciences fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(191.14 K) | 6.65 M | 809.59 K | 14.93 M |
Xenetic Biosciences Investor Information
About 19.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.94. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Xenetic Biosciences recorded a loss per share of 2.66. The entity last dividend was issued on the 25th of June 2019. The firm had 1:10 split on the 15th of May 2023. Based on the key indicators related to Xenetic Biosciences' liquidity, profitability, solvency, and operating efficiency, Xenetic Biosciences may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Xenetic Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Xenetic Biosciences has an asset utilization ratio of 23.95 percent. This suggests that the Company is making $0.24 for each dollar of assets. An increasing asset utilization means that Xenetic Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Xenetic Biosciences Ownership Allocation
Xenetic Biosciences maintains 19.05 (%) of its outstanding shares held by insiders and 2.09 (%) owned by institutional investors.Xenetic Biosciences Profitability Analysis
The company reported the previous year's revenue of 2.54 M. Net Loss for the year was (4.13 M) with profit before overhead, payroll, taxes, and interest of 2.52 M.About Xenetic Biosciences Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Xenetic Biosciences. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Xenetic Biosciences based exclusively on its fundamental and basic technical indicators. By analyzing Xenetic Biosciences's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Xenetic Biosciences's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Xenetic Biosciences. We calculate exposure to Xenetic Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Xenetic Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.9 M | 1.6 M | |
| Pretax Profit Margin | (1.47) | (1.54) | |
| Operating Profit Margin | (1.60) | (1.68) | |
| Net Loss | (1.47) | (1.54) | |
| Gross Profit Margin | 0.89 | 0.77 |
Xenetic Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.5 M |
Xenetic Biosciences Current Valuation Indicators
Xenetic Biosciences' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Xenetic Biosciences' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Xenetic Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Xenetic Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Xenetic Biosciences' worth.When determining whether Xenetic Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Xenetic Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xenetic Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xenetic Biosciences Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Revenue Per Share | Quarterly Revenue Growth 0.116 | Return On Assets | Return On Equity |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.